EP2968293A4 - PAIN RELIEF COMPOSITIONS COMPRISING AN OPIOID / TOLL LIKE RECEPTOR 4 ANTAGONIST, DEXTROENANTIOMERS, AND METHOD OF USE THEREOF - Google Patents

PAIN RELIEF COMPOSITIONS COMPRISING AN OPIOID / TOLL LIKE RECEPTOR 4 ANTAGONIST, DEXTROENANTIOMERS, AND METHOD OF USE THEREOF

Info

Publication number
EP2968293A4
EP2968293A4 EP14773349.7A EP14773349A EP2968293A4 EP 2968293 A4 EP2968293 A4 EP 2968293A4 EP 14773349 A EP14773349 A EP 14773349A EP 2968293 A4 EP2968293 A4 EP 2968293A4
Authority
EP
European Patent Office
Prior art keywords
toll
pain
receptor
methods
opioid antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP14773349.7A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2968293A1 (en
Inventor
Annette Channa Toledano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allodynic Therapeutics LLC
Original Assignee
Allodynic Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/799,287 external-priority patent/US20130310412A1/en
Priority claimed from US13/837,099 external-priority patent/US9095548B2/en
Priority claimed from US13/841,100 external-priority patent/US9205081B2/en
Priority claimed from US13/851,267 external-priority patent/US20150111916A9/en
Priority claimed from US13/851,773 external-priority patent/US20150111917A9/en
Application filed by Allodynic Therapeutics LLC filed Critical Allodynic Therapeutics LLC
Publication of EP2968293A1 publication Critical patent/EP2968293A1/en
Publication of EP2968293A4 publication Critical patent/EP2968293A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP14773349.7A 2013-03-13 2014-03-13 PAIN RELIEF COMPOSITIONS COMPRISING AN OPIOID / TOLL LIKE RECEPTOR 4 ANTAGONIST, DEXTROENANTIOMERS, AND METHOD OF USE THEREOF Ceased EP2968293A4 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US13/799,287 US20130310412A1 (en) 2010-06-28 2013-03-13 Combinations of an Opioid/TLR4 Antagonist and a Direct-Acting Alpha-2 Adrenergic Agonist for Use in the Treatment of Pain
US13/837,099 US9095548B2 (en) 2010-04-29 2013-03-15 Combinations of opioid/TLR4 antagonists and acetyl-para-aminophenol (APAP) for use in the treatment of pain
US13/841,100 US9205081B2 (en) 2010-04-29 2013-03-15 Combinations of opiod/TLR4 antagonist and a cyclooxygenase (COX) inhibitor for use in the treatment of pain
US13/851,267 US20150111916A9 (en) 2010-04-29 2013-03-27 Treatment of pain using a composition of opioid/Toll-like receptor 4 antagonists and dextro enantiomers thereof
US13/851,773 US20150111917A9 (en) 2010-04-29 2013-03-27 Combinations of an Opioid/TLR4 Antagonist and an Alpha-2-Delta Ligand for Use in the Treatment of Pain
PCT/US2014/025771 WO2014160077A1 (en) 2013-03-13 2014-03-13 Compositions to reduce pain comprising an opioid/toll-like receptor 4 antagonist, dextro enantiomers thereof, and methods of use therefor

Publications (2)

Publication Number Publication Date
EP2968293A1 EP2968293A1 (en) 2016-01-20
EP2968293A4 true EP2968293A4 (en) 2016-12-28

Family

ID=51625328

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14773349.7A Ceased EP2968293A4 (en) 2013-03-13 2014-03-13 PAIN RELIEF COMPOSITIONS COMPRISING AN OPIOID / TOLL LIKE RECEPTOR 4 ANTAGONIST, DEXTROENANTIOMERS, AND METHOD OF USE THEREOF

Country Status (5)

Country Link
EP (1) EP2968293A4 (enExample)
JP (1) JP2016512561A (enExample)
AU (1) AU2014244152A1 (enExample)
CA (1) CA2942641A1 (enExample)
WO (1) WO2014160077A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016105449A1 (en) * 2014-12-22 2016-06-30 Seth Lederman Compounds for use as pain therapeutics
CA2996281C (en) * 2015-08-31 2022-03-08 Regents Of The University Of Minnesota Opioid receptor modulators and use thereof
RU2742337C2 (ru) * 2016-09-09 2021-02-04 Такеда Фармасьютикал Компани Лимитед Циклическое соединение
WO2018081792A2 (en) 2016-10-31 2018-05-03 Allodynic Therapeutics, Llc Combinations of opioid/tlr4 antagonists and acetaminophen for use in the treatment of emotional pain and insomnia
US12472158B2 (en) 2019-02-27 2025-11-18 Vanderbilt University Methods of treating trigeminal nerve pain
WO2025259600A2 (en) * 2024-06-10 2025-12-18 University Of Rochester Brain protein targets for the treatment of migraine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1813283A1 (en) * 2004-11-05 2007-08-01 Japan Science and Technology Agency Remedy for neuropathic pain
US20110159048A1 (en) * 2009-12-22 2011-06-30 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200001942T2 (tr) * 1997-12-22 2000-11-21 Euro-Celtique, S.A. Opioid agonist/antagonist kombinasyonlar
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US20070060500A1 (en) * 2000-08-22 2007-03-15 New River Pharmaceuticals Inc. Pharmaceutical compositions for prevention of overdose or abuse
US20040192715A1 (en) * 2003-02-05 2004-09-30 Mark Chasin Methods of administering opioid antagonists and compositions thereof
GB2447014A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
EP2240022B1 (en) * 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
US20110269727A1 (en) * 2010-04-29 2011-11-03 Toledano Annette C Composition to reduce allodynic back pain and related method of use
WO2012048294A2 (en) * 2010-10-07 2012-04-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1813283A1 (en) * 2004-11-05 2007-08-01 Japan Science and Technology Agency Remedy for neuropathic pain
US20110159048A1 (en) * 2009-12-22 2011-06-30 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2014160077A1 *

Also Published As

Publication number Publication date
WO2014160077A1 (en) 2014-10-02
EP2968293A1 (en) 2016-01-20
AU2014244152A1 (en) 2015-10-01
CA2942641A1 (en) 2014-10-02
JP2016512561A (ja) 2016-04-28

Similar Documents

Publication Publication Date Title
EP2688403A4 (en) OPIOID RECEPTOR LIGANDS AND METHOD FOR THEIR USE AND MANUFACTURE
EP2830629A4 (en) COMPOSITIONS AND METHOD FOR THE REACTIVATION OF LATENT IMMUNE FIZIENZVIRUS
EP2753605A4 (en) COMPOSITIONS, METHODS AND SYSTEMS FOR SYNTHESIS AND USE OF CONTRASTING AGENTS
EP2978300A4 (en) COMPOSITIONS AND METHODS FOR INCREASING MICROBIAL STABILITY
EP2882719A4 (en) COMPOSITIONS, METHODS AND SYSTEMS FOR SYNTHESIS AND USE OF CONTRASTING AGENTS
EP2759092A4 (en) SYSTEMS AND METHOD FOR SAFE USER IDENTIFICATION
EP2917265A4 (en) COMPOSITION FOR METAL GALVANIZATION WITH LENGTH
EP2837374A4 (en) CARRIER OF A COSMETIC COMPOSITION WITH FOAMS
EP2834322A4 (en) BIOKOHLEZ COMPOSITIONS AND METHOD FOR USE THEREOF
EP2819623A4 (en) URINAUGHTER FOR WOMEN
EP2663367A4 (en) USE OF GREAT-SIMILAR RECEPTOR AGONISTS FOR THE TREATMENT OF CANCER
EP2928495A4 (en) COMPOSITIONS WITH ANTI-CD38 ANTIBODIES AND LENALIDOMIDE
EP2626807A4 (en) BASED ON TWO FACTORS USER AUTHENTICATION SYSTEM AND METHOD THEREFOR
EP2928625A4 (en) BODENSANIERUNG COMPOSITION
EP2854781A4 (en) XYLITOL-BASED ANTIMUKOSAL COMPOSITIONS AND ASSOCIATED METHODS AND COMPOSITIONS
EP3050409A4 (en) HANDLES FOR HOLDING FASTENERS FOR EXPANSION CARDS
EP2751135A4 (en) VEGF-SPECIFIC IMPORTERS, COMPOSITIONS AND METHOD FOR THEIR USE AND MANUFACTURE
EP2878139A4 (en) METHOD AND DEVICES FOR EASIER USE OF CLOUD SERVICES
EP2968237A4 (en) METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
EP2941534A4 (en) SYSTEMS AND METHOD FOR ASSESSING DEEP FORMATIONS
EP2821006A4 (en) FUNDUS COPY DEVICE
EP2858342A4 (en) IMAGING DEVICE
DK2858563T3 (da) Elektromedicinsk system til bestemmelse af neuromuskulkær lammelse
EP2678359A4 (en) COMBINATION THERAPIES WITH ANTI-ERBB3 MEDIUM
EP2976900A4 (en) BUILDING TERMS AND CONDITIONS FOR LOCATION-BASED SERVICES

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151013

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/44 20060101AFI20160816BHEP

Ipc: A61K 31/485 20060101ALI20160816BHEP

Ipc: A61K 31/4168 20060101ALI20160816BHEP

Ipc: A61P 25/00 20060101ALI20160816BHEP

Ipc: A61K 9/08 20060101ALI20160816BHEP

Ipc: A61K 9/20 20060101ALI20160816BHEP

Ipc: A61K 45/06 20060101ALI20160816BHEP

Ipc: A61K 31/167 20060101ALI20160816BHEP

Ipc: A61K 31/197 20060101ALI20160816BHEP

Ipc: A61K 31/192 20060101ALI20160816BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20161130

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20161124BHEP

Ipc: A61K 31/167 20060101ALI20161124BHEP

Ipc: A61K 31/485 20060101ALI20161124BHEP

Ipc: A61K 31/44 20060101AFI20161124BHEP

Ipc: A61K 31/192 20060101ALI20161124BHEP

Ipc: A61P 25/00 20060101ALI20161124BHEP

Ipc: A61K 31/4168 20060101ALI20161124BHEP

Ipc: A61K 9/20 20060101ALI20161124BHEP

Ipc: A61K 31/197 20060101ALI20161124BHEP

Ipc: A61K 9/08 20060101ALI20161124BHEP

17Q First examination report despatched

Effective date: 20170920

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20190126